Cobalt-chromium stent reduces stent thrombosis

Release date: 2008-11-03

The results of human experiments using the first polymer-coated cobalt-chromium stents for the first time are encouraging, suggesting that this device can reduce the potential for post-stent thrombosis. The investigators reported that patients with this stent had no stent thrombosis after 12 months, although the patient discontinued dual antiplatelet therapy 30 days after surgery and had no clinical side effects.

Dr. Corrado Tamburino of Ferrarotto Hospital in Catania, Italy, said: "This polymer has some unique properties, first of all it is very very thin; secondly, the surface of the stent has also been modified to be biosoluble, and the polymer has anti-inflammatory properties. And antithrombotic properties. So we can stop dual antiplatelet therapy without causing an increased incidence of stent thrombosis."

The new stent, called Catania, was produced by CeloNova Biosciences, and the results were called the ATLANTA experiment, which was announced at the 2008 TCT Conference.

In an interview with Heart Online, Dr. Tamburino explained that the cobalt-chromium stent was modified to include a synthetic inorganic polymer called Polyzene-F, which was previously shown to be antithrombotic and anti-inflammatory. characteristic. The purpose of using this polymer coated scaffold is to help promote healthy endothelial cell growth without stimulating platelet activation.

In this prospective, single-center, non-randomized study, 55 patients were fitted with a Catania stent. After 12 months, there was no report of stent thrombosis. In clinical events, there are no deaths, myocardial infarctions, cerebrovascular diseases, or coronary artery bypass surgery. At 12 months, the re-conservation rate after target tissue injury was 10.9%, and the restenosis rate was 6.8%. All patients discontinued dual antiplatelet therapy after 30 days and continued taking aspirin 100 mg daily for 12 months of follow-up. Fifteen of them underwent intensive CT, and the researchers reported complete endothelial cell growth, with 99.5% of the stent covered after six months.

Tamburino told Heart Online that his institute is currently conducting a registration analysis of 160 different patients with Catania stents, including some patients with dual antiplatelet therapy contraindications. Although many patients only use aspirin, there are no reports of stent thrombosis.

The author said: "This stent requires more research and randomized, controlled clinical trials. But I personally believe this stent. I think it is a safe product, especially bleeding or hemorrhagic stroke. High-risk patients may benefit more."

Catania stents have been CE certified and can only be sold outside the United States. ——Shanghai Medical Device Industry Association

Royal Jelly is also called Bee Milk. The fresh royal jelly is slightly ropy milk paste  substance; it is the excretive mixture of nutrition gland and maxilla gland of the head of little worker bee. The worker bees use this to feed the 1-3 days` worker bee larva and drone larva, 1-5.5 days` queen bee larva and queen bee in the oviposition period. The royal jelly is the biologic product containing very complicated active elements which contains almost all the nutrition elements required by the growth of the human body.

Royal Jelly

Royal Jelly,Natural Royal Jelly,Healthy Royal Jelly,Organic Fresh Royal Jelly

Easy Food (Jiaxing) Co., Ltd. ,